Box 1.

It is important to select the right patient for SGLT2 inhibitor therapy and avoid in others who may be at high risk of DKA.¹⁸ The following patients are likely to benefit most.

Adults above 18 years with T2D and one or more of the following:
- established / high risk of cardiovascular disease^a
- chronic kidney disease with albuminuria^a
- history of heart failure^a
- inadequate glycaemic control with need to minimise hypoglycaemia
- inadequate glycaemic control with need to minimise weight gain / encourage weight loss.
Patients with a clear understanding of the risks associated with SGLT2 inhibitors and how to reduce those risks.

↵^aPlease refer to Table 1 for evidence of benefit for individual agents. DKA = diabetic ketoacidosis; SGLT2 = sodium glucose co-transporter 2.